The carbonic anhydrase inhibitor acetazoleamide, (2-acetylamino-1,3,4-thiadazole-5 sulfonamide, 6063, Diamox®), is believed to decrease the exchange of hydrogen for sodium ions in the renal tubule (1) . Alkalinization of the urine with sodium, potassium, and bicarbonate diuresis is found after its administration, both in normal people and in patients with cardiac failure (2) . Except for the report by Metcoff, James, and Gordillo in nephrosis (3) , no data are available concerning the effect of acetazoleamide in primary renal disease. This investigation was undertaken to see if the effect in patients with renal disease was the same as in normal people, and to evaluate any possible therapeutic benefit from the use of the drug.
The action of acetazoleamide is believed to be limited to the carbonic anhydrase enzyme system, and this suggested that it could be used to determine the presence of functioning renal carbonic anhydrase. The occurrence of the customary urine changes after administration of acetazoleamide would then indicate the presence of functioning carbonic anhydrase in the kidney.
MATERIAL AND METHODS
The subjects used for this investigation included four healthy young males and fifteen patients who were selected because of the presence of severe renal disease. Each patient's clinical status was steady at the time of study. None had diarrhea or vomiting. The individual diagnoses are shown in Table I , with clinical data and details of tests obtained within a few days of acetazoleamide administration, in the Appendix. All subjects were in bed overnight and were in a basal post-absorptive state, remaining recumbent throughout the procedure. An indwelling urethral catheter containing multiple holes in the tip was inserted into the bladder at least two and one-half hours before the start of the first collection period in all subjects, except in the case of the normal males M. K. and J. B. who voided spontaneously under oil.
Exposure of the urine to air was avoided in all. In the first eleven cases studied, the catheter was connected by a short length of rubber tubing and the urine allowed to drain into a container under a layer of mineral oil. In the last six cases, urine was withdrawn directly into oiled 50 cc. syringes. Specimens were kept on ice until analysed the same morning. Water, 120 cc. to 300 cc. depending on body weight, was taken orally at (6) . Titratable acidity was determined by the method of Henderson and Palmer (7), the end point being checked using a pH meter. Ammonia nitrogen was determined by the continuous aeration technique (8 Table I and presented graphically in Figure 1 .
Group I-Normal subjects
The response to the administration of acetazoleamide in the four normal subjects was similar to that described previously in both man (2) and the dog (9), consisting of a moderate increase in urine volume and a rise in urine pH over 7.4 with diminution in titratable acid and ammonia. There was a marked increase in sodium and bicarbonate excretion with a smaller rise in potassium loss. Any change in chloride loss was inconstant but phosphate excretion increased slightly.
Group II-Renal disease uithout acidosis There were six patients in this group all of whom had normal plasma bicarbonate levels except for T. W., in whom it was 19.4 mEq. per L. This was associated with vomiting before admission and the presence of a large empyema. All patients showed a response to the drug. There was, however, a significant decrease in sodium and bicarbonate loss as compared with Group I, with potassium tending to be the major cation accompanying the increase in excreted bicarbonate. This was most marked in the patients with the smallest increments in sodium excretion. Changes in urine volume, pH, titratable acid and ammonia were similar in the two groups.
Group III 
Group IV-Renal tubular acidosis
Three patients with this syndrome were studied. C. B. had a plasma bicarbonate level of 20.1 mEq. per L. and he showed the usual urinary changes after acetazoleamide. M. B. and F. P. with plasma bicarbonates of 14.0 mEq. per L. and 14.8 mEq. per L., respectively, showed no urinary changes after the inhibitor when acidotic, but definite changes after correction of the acidosis with sodium citrate. Comparison of the individual values of this group with the other groups is difficult owing to the effect of treatment superimposed on the basic urinary abnormality. Nevertheless, the increment in sodium and bicarbonate excretion after acetazoleamide is the same in magnitude in these three patients as in the patients in Group II.
Group V-Ammonium chloride acidosis
To determine more precisely the effect of acidosis alone without renal disease in conditioning the response to acetazoleamide, the two normal subjects M. K. and J. B. each ingested 374 mM of ammonium chloride in gelatin capsules. This was taken in evenly divided amounts from 9 a.m. to 10.30 p.m. the day before taking acetazoleamide. The plasma bicarbonate at the end of the control periods was reduced to one-half of the value found the previous day before taking ammonium chloride. In both instances, there was partial blocking of acetazoleamide effect as indicated by absence of the customary sodium and bicarbonate diuresis. The change in the rate of ammonia and titratable acid excretion was probably due to withdrawal of the acid load rather than to acetazoleamide.
A further experiment was performed in which an attempt was made to keep the intracellular pH normal whilst at the same time creating an extracellular acidosis. M. K. ingested 336 mM of ammonium chloride and 111 mM of potassium chloride under the same conditions as in the previous two experiments. There was no difference, however, in the effect of acetazoleamide. Similar depression of serum bicarbonate was produced in both instances and with the supplementary potassium, the serum potassium rose from 3.93 mEq. per L. to 6.51 mEq. per L.
DISCUSSION
The demonstration that metabolic acidosis blocks the effect of oral acetazoleamide in man is in complete agreement with the findings of Maren and Wadsworth in dogs (10) . Reports of other workers stating that acetazoleamide exerts its customary action in metabolic acidosis ( 1, 11 ) are probably explained by the mild degree of acidosis in these experiments. From the present data, the blocking effect of metabolic acidosis was demonstrated in patients with renal disease when the plasma bicarbonate was 19 mEq. per L., or below. In the normal controls, this effect was observed when the plasma bicarbonate was in the neighbourhood of 16 mEq. per L.
Several possible mechanisms may be considered to explain the apparent lack of effect of acetazoleamide in metabolic acidosis. Impaired absorption of the drug is unlikely as it is known in the dog to be well absorbed from the gastro-intestinal tract with production of adequate blood levels even in the presence of metabolic acidosis (9) . Also, in ammonium chloride acidosis in the dog, the effect of acetazoleamide is still blocked after intravenous administration (12) .
No change in the pharmacological activity of acetazoleamide occurs within the intracellular pH range compatible with life (12) . Furthermore, any change in the activity of carbonic anhydrase within this pH range is minimal (13) . If an increased activity or amount of enzyme is assumed, then increasing the dose of inhibitor sufficiently would be expected to produce the usual urinary changes. However, even with doses as large as 100 mg. per kg. in the dog, only 20 per cent of the expected bicarbonate excretion occurs in the presence of ammonium chloride acidosis (12) .
It has been shown that the majority of the filtered base bound to bicarbonate is reabsorbed by a process of ion exchange with hydrogen ions secreted by the tubule (14, 15) . The number of hydrogen ions secreted at any time, other things being constant, presumably depends on their availability within the tubular cell. The major contribution to this supply will be from the hydration of carbon dioxide, catalyzed by carbonic anhydrase as shown by the reaction C.A.
CO2 + H2O0=±H2COs
H2CO3a=>H+ + HCO37.
If the concentration of hydrogen ions within the cell was increased secondary to changes in the extracellular fluid pH, then it would be expected that proportionally less of the secreted hydrogen ions would originate through the action of carbonic anhydrase. Inhibition of the enzyme with acetazoleamide might then have less effect on base reabsorption than usual.
Conversely, decreasing the intracellular hydrogen ion concentration by infusion of sodium bicarbonate would make the enzymatic hydration process the principal source of hydrogen ions. Inhibition of the enzyme under these circumstances indicates that a larger than usual amount of bicarbonate escapes reabsorption (16, 17) .
Leaf, Schwartz, and Relman (18) have suggested that with reduction in the filtered load of bicarbonate, fewer hydrogen ions are required for adequate base reabsorption. Less response might therefore be seen after carbonic anhydrase inhibition. This does not explain the absence of acetazoleamide effect in ammonium chloride acidosis where high rates of hydrogen ion secretion are found.
With reduction in renal mass by disease, a decrease in the carbonic anhydrase content of the kidney would be expected. Enzyme inhibition might then cause smaller urinary changes as compared with the changes produced in normal controls. The smaller increment in sodium and bicarbonate excretion in the patients with renal disease without acidosis is compatible with this. However, the changes in urine volume, pH, potassium, ammonia, and titratable acid were not statistically different from the controls. This may be due to the small size of each group. It is also possible that although hydrogen ion secretion was effectively blocked, other tubular mechanisms ensured less sodium excretion than usual. In regard to this, the increased exchange of potassium for sodium is of interest and has been noted previously (19, 20) .
In the patients with acidosis, the absence of any urinary changes after using acetazoleamide could be caused both by the acidosis itself and in addition by the other mechanisms discussed above.
The syndrome of idiopathic renal tubular acidosis has been suggested as being due to a deficiency of carbonic anhydrase in the renal tubules (1, 21) . The excretion of an alkaline urine containing large amounts of base is similar to the urines produced after administration of acetazoleamide. In the three cases in this series, all showed evidence of functioning renal carbonic anhydrase. This suggests that some other metabolic abnormality, perhaps involving the transport of hydrogen ions rather than their production is at fault in this condition.
Except for transitory drowsiness and occasional headache, no side effects were observed in these patients. Even in those with advanced renal failure, no evidence of untoward effect was seen in the urine, blood pressure, or degree of azotemia, after the use of acetazoleamide. In view of the relative freedom from toxic manifestations to date, the drug might be considered as an adjunct in the treatment of patients with primary renal disease, or in other conditions complicated by renal disease where fluid retention exists. It might also be of value when alkalinization of the urine, or potassium loss is desired. The presence of azotemia, hypertension, or marked reduction in functional tests do not themselves contraindicate the use of the drug. However, if there is acidosis with a plasma bicarbonate below 19 mEq. per L. then there will be no effect from its administration. A further limiting factor in the use of acetazoleamide as a diuretic in renal disease is the smaller increment in sodium excretion as compared to that found in normal people. It does not seem possible to predict beforehand the magnitude of this loss because of the large individual variation.
SUMMARY
The effect of a single oral dose of the carbonic anhydrase inhibitor, acetazoleamide, was studied in fifteen patients with renal disease and four normal controls. In the normal subjects, there was an increase in urine volume, rise in urine pH, with sodium, potassium and bicarbonate diuresis. This effect was also produced in patients with renal disease without acidosis, but was smaller in magnitude. In the patients with renal disease and metabolic acidosis however, the urinary changes were minimal or absent completely.
Following production of ammonium chloride acidosis in two normal subjects, acetazoleamide failed to produce the customary urinary changes.
The reason for these findings and the possible therapeutic value of acetazoleamide in renal disease was discussed. 
